Irene is the Senior Director of Boston Children’s Hospital’s Technology & Innovation Development Office, the organization responsible for commercializing discoveries made at Boston Children’s Hospital. She has held positions at Partners Healthcare Innovation, where she was responsible for commercializing MGH discoveries; Brandeis University, as Associate Provost for Innovation, and M.I.T., as a Senior Technology Licensing Officer. Irene has designed and run virtual incubator programs at Partners and Brandeis and is the past President of the Massachusetts Association of Technology Transfer Offices, the founder of T3, and an Associate VP of the Association of University Technology Managers.
Alan H. Beggs, PhD, is director of The Manton Center for Orphan Disease Research at Boston Children's Hospital, a scientist in the hospital's Division of Genetics and Genomics, and a Professor of Pediatrics at Harvard Medical School. He is an authority on the genetic underpinnings of congential myopathies, a group of little-understood, inherited disorders causing muscle weakness. Dr. Beggs is also the principal investigator on the five year, NIH-funded, BabySeq study, which will asses the outcomes, benefits, and risks of DNA sequencing. He is part of the NIH's Undiagnosed Diseases Network and co-organizer of the CLARITY Undiagnosed Challenge.
Charles Berde, MD, PhD is the Sara Page Mayo Chair in Pediatric Pain Medicine, Chief of the Division of Pain Medicine at Boston Children's Hospital (BCH) and Professor of Anaesthesia (Pediatrics) at Harvard Medical School. Dr. Berde directs the Pain Treatment Service at BCH, the first and most clinically active acute and chronic pain management program for children in the world. His clinical research includes pharmacology of analgesics and local anesthetics in children, clinical outcomes of treatment of neuropathic pain and cancer pain in children, functional brain imaging of children with neuropathic pain and brain dynamic studies in children during general anesthesia. Translational research on novel prolonged duration local anesthetics has progressed from the Berde laboratory to clinical trials.
Aman Bhandari runs corporate partnerships focused on data, technology and innovation at Merck & Co. Prior to Merck, Aman worked on President Obama’s Tech Team at the White House and was also a senior researcher at the Centers for Medicare and Medicaid Services (CMS). While in government he played a critical role in the implementation of the President's Open Data and Open Government initiatives. His work in the health sector served as a blueprint for open data efforts across sectors and for initiatives such as the Presidential Innovation Fellows program. Aman has advised data, tech and innovation initiatives from the World Bank, USAID, Academy Health, Harvard, Cornell, Ashoka Foundation, Knight News Foundation, Prebacked Ignition Health, SXSW Health and others. He holds a PhD in health policy research from the University of California, Berkeley.
Dr. John Brownstein serves as Chief Innovation Officer at Boston Children's Hospital. Dr. Brownstein was trained as an epidemiologist at Yale University where he received his PhD. His research interests are in the development of methods and data sources in public health informatics which focuses on two major areas: (1) the design, evaluation and implementation of public health surveillance systems and (2) statistical modeling of public health surveillance data to improve prevention and control activities.John Brownstein, PhD:
Catherine Brownstein, MPH, PhD, is a research associate in Genetics and Genomics and manager of the Molecular Genomics Core Facility at Boston Children's Hospital, as well as Instructor of Pediatrics at Harvard Medical School. Dr. Brownstein has worked to develop research sequencing and pharmacogenomics programs, and has recently signed on as a lead for the “Transitions of Care” team for the NIH’s Undiagnosed Diseases Network Coordinating Center. She has over 10 years of experience in genetics and toxicology. Previously, Dr. Brownstein worked as a toxicologist for the Massachusetts Department of Public Health and at various startups in Health 2.0.Catherine Brownstein, MPH, PhD:
Hubert Caron, MD, PhD, Senior Medical Director of Pediatric Oncology at Roche and Research Professor at AMC, Amsterdam. Dr. Caron is the clinical study lead (CSL) in the team for “innovative Pediatric Oncology Drug Development” (iPODD) for the clinical trials in the MATRIX master protocol for children with cancer. He is also leading the development of a preclinical pediatric screening platform to support rational Mechanism-of-Action based development of the Roche Genentech anticancer drugs in the “best fitting” pediatric cancers. At AMC he is principal investigator for several tumor-biology-driven preclinical translational research projects aimed at improving therapy and risk-stratification of childhood neuroblastoma.
A renowned music manager, Carter is the Founder and CEO of Atom Factory, a pioneering media and music management company. He has established the careers of numerous recording artists, including multi-platinum Grammy-Award winner Lady Gaga and was recently announced as an upcoming guest shark on ABC's Shark Tank. A brand and corporate strategist, his portfolio of investments and startup endeavors read as a summary of the hottest trends in today's technology landscape. In 2011, he founded AF Square, an angel fund and technology consultancy. Today, the AF Square portfolio holds interest in more than 60 technology companies at various stages of growth, including Uber, Dropbox, Spotify, Fab, Pinterest and Lyft. Carter is an Aspen Institute Henry Crown Fellow and sits on the boards of The Grammy Foundation, T.J. Martell Foundation, United Nations Foundation Global Entrepreneurs Council and The Buckley School.
Aneesh Chopra is the co-founder and executive vice president of Hunch Analytics, a “hatchery” incubating ideas that improve the productivity of health and education markets, including NavHealth, an open data intelligence service. From '09-'12, Chopra served as the first U.S. Chief Technology Officer with a focus on better public/private collaboration as described in his 2014 book, "Innovative State: How New Technologies can Transform Government." He was named to Modern Healthcare's list of the 100 Most Influential People in Healthcare in 2011. Chopra earned his master's degree in public policy from Harvard Kennedy School and his bachelor's degree from The Johns Hopkins University.Aneesh Chopra:
Wendy Chung, MD, PhD, directs the clinical genetics program at Columbia University and performs human genetic research. She is an associate professor of pediatrics and medicine. She received her MD from Cornell University Medical College, and a PhD from The Rockefeller University in genetics. Dr. Chung directs NIH funded research programs in human genetics of obesity, breast cancer, pulmonary hypertension, and birth defects including congenital diaphragmatic hernia and congenital heart disease. She leads the Simons VIP study characterizing genetic forms of autism and tests novel treatments for autism in clinical trials. She received the American Academy of Pediatrics Young Investigator Award, Bonei Olam's Medical Achievement Award, and a career development award from Doris Duke.
George is Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT). He is Director of the U.S. Department of Energy Center on Bioenergy at Harvard and MIT and Director of the National Institutes of Health Center of Excellence in Genomic Science at Harvard. His has received numerous awards including the 2011 Bower Award and Prize for Achievement in Science from the Franklin Institute, the 2009 Promega Biotechnology Research Award from the American Society for Microbiology, and the number four spot on the 2008 list of The Scientist's top ten innovations.George Church, PhD:
Dr. Kevin Churchwell is Chief Operating Officer and Executive Vice President of Health Affairs for Boston Children’s Hospital. Churchwell previously served as the CEO of Nemours/Alfred I. duPont Hospital for Children in Wilmington, Del. Churchwell has strong ties to the Boston area, graduating with an undergraduate degree from MIT and completing his residency at Boston Children’s, in addition to serving as an attending physician there for two years. Churchwell has a medical degree from Vanderbilt University. He previously served as CEO of Vanderbilt Children’s Hospital.
Jane Clayson has risen to national prominence as co-host of a network morning news program and has covered high-profile national and international stories for both CBS News and ABC News. She has hosted interviews with U.S. Presidents, world leaders, and Martha Stewart prior to her federal indictment, and her work as a CBS news correspondent included specials on Elizabeth Smart and Jessica Lynch.
Robert K. Coughlin is President and CEO of the Massachusetts Biotechnology Council. His mission is to foster a positive environment that enables each biotechnology company to achieve its full potential in Massachusetts, making the state a world center for biotechnology. He is a passionate advocate for research and the biotechnology community.Robert Coughlin:
William Crawford is a VP of Engineering and head of the Boston Office of Fitbit , the leader in wearable technology and activity tracking. Before Fitbit he was the CEO of Linked Medical, a spinoff from Massachusetts General Hospital focusing on next generation point of care technology for general medicine. Mr. Crawford previously held senior roles at Boston Children's Hospital, PAREXEL and the Centers for Medicare and Medicaid Services, all focused on connected technology and finding new and better ways to share information on behalf of and to the benefit of patients. He holds an undergraduate degree from Yale along with graduate degrees from MIT’s Sloan School of Management and the Harvard-MIT Division of Health Sciences and Technology.
Deborah DiSanzo is the General Manager for IBM Watson Health, the business unit founded to achieve IBMs next ‘moonshot’: to advance health at a global scale. She leads more than 2,000 IBMers worldwide from the unit’s headquarters in Cambridge, Massachusetts. Deborah has a distinguished career working at the intersection of healthcare and technology. Prior to joining IBM, she was CEO of Philips Healthcare, a $10 billion euro healthcare technology company. Previously, she held management roles at Hewlett-Packard and Apollo Computer.Deborag DiSanzo:
Chris Duffy is the creator and host of You're the Expert, a live show and public radio program on WBUR where three comedians try to guess what a scientist studies all day. Chris is also a standup comedian and improviser who has performed at colleges and festivals throughout the country (including SF Sketchfest, Caltech, Brown, Harvard, the Eugene Mirman Comedy Festival, the Cambridge Science Festival, and more).Chris Duffy:
As President and CEO of Boston Children's Hospital, Sandra L. Fenwick leads Boston Children's in advancing pediatric health care throughout the region and around the world, working to improve access to safe, quality care for all, and supporting the research and innovative partnerships required to lead the way in creating the future of care.
Nicole Fisher is the Founder and CEO at HHR Strategies, a health care and human rights focused advising firm. Additionally, she is a Senior Policy Advisor for federal and state officials and an expert on health reform, specifically as they impact vulnerable populations around the world. Nicole runs a Health Innovation and Policy page at Forbes highlighting and advising companies, ideas and people that are changing the health care landscape and curates a monthly, private thought leadership dinner series: A Seat At The Table. She presides on several Boards for domestic and international health organizations and frequently speaks on health, innovation and human rights.Nicole Fisher:
Dr. Stephen Friend is CEO and co-founder at Sage Bionetworks, a non-profit organization with a goal to create a global integrative bionetwork community where researchers and the public are rewarded for collaborating. Most recently, he coordinates Sage Bionetwork’s efforts on several of Apple’s Open Source ResearchKit apps including the building of these apps and the building out of the back-end so that qualified researchers worldwide can share their data on “Synapse” which is an Open Biomedical Research Platform. Dr. Friend was on the faculty at Harvard Medical School, Massachusetts General Hospital and University of Washington before becoming a full member at the Fred Hutchinson Cancer Research Center. He founded and co-led the ‘Seattle Project’, which evolved into Rosetta Inpharmatics and was acquired by Merck & Company in '01.Stephen Friend, MD, PhD:
Nancy founded Kids v Cancer, which promotes pediatric cancer research by identifying structural impediments at key junctures in the research process— access to funding, tissue and drugs – and developing strategies to resolve them. She is working with Members of Congress to pass the Kids’ Innovative Drugs Initiative to require and incentivize drug companies developing drugs for adult cancers to also develop those drugs for children with cancer. Nancy has served on the FDA pediatric Oncology Drug Advisory Committees and on the NCI Board of Scientific Counselors. She is a lawyer and studied at Harvard’s Kennedy School of Government, the University of Chicago Law School, and Harvard Law School.
Dr. Hood has played a role in founding 15 biotechnology companies including Amgen, Applied Biosystems, Integrated Diagnostics and Arivale. He is a member of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine (one of only 15 people nominated to all three). Dr. Hood has co-authored textbooks in biochemistry, immunology, molecular biology and genetics, and a popular book on the human genome project. In addition to having received 17 honorary degrees, Dr. Hood has published >750 peer reviewed articles and currently holds 36 patents. In 2013, he received the National Medal of Science from President Obama. Scientific American has named Hood as one of the top 6 in their selection of 100 biotech visionaries world-wide (2015).Leroy Hood, MD, PhD:
Katherine A. Janeway, MD is a Senior Attending Physician in Pediatric Hematology-Oncology at Dana-Farber Cancer Institute and Boston Children’s Hospital and an Professor of Pediatrics at Harvard Medical School. Her primary areas of research focus are: 1) understanding the application of cancer genomics to the pediatric oncology clinic and 2) identifying central oncogenic mechanisms, novel drug targets and new therapeutics for pediatric sarcomas. She received her MD and Masters in Medical Science from Harvard, completed her residency in Pediatrics at Boston Children's, where she later served as Chief Resident. Dr. Janeway completed her fellowship in Pediatric Hematology-Oncology at Dana-Farber Cancer Institute/Boston Children’s Hospital, where she joined the staff in 2007.
Tammi Jantzen is General Partner and CFO of Astarte Ventures, a venture fund dedicated exclusively to the health and wellbeing of women and children. Astarte was formed to focus exclusively at the intersection of new care models, increasing consumer engagement in health, and women’s role in the economy and as decision makers. In addition, Tammi is CFO of Battelle Ventures, where she manages all aspects of fund operations. With more than 15 years of venture capital experience and an in-depth knowledge of the diversity of deal types at varying stages of maturity, Tammi actively collaborates on the structuring of financial transactions and participates in the review and negotiation of deal documents.Tammi Jantzen:
Jared Kesselheim joined Bain Capital Ventures in 2008 to focus on healthcare and has been actively involved in investments in healthcare information technology, healthcare services, and diagnostics. Prior to joining Bain as Partner, Jared completed his residency in internal medicine at the Massachusetts General Hospital. Jared has also worked at McKinsey & Company and the Massachusetts General Physicians Organization. Jared received his MD from Harvard Medical School and his MBA with high distinction from Harvard Business School, where he was a Baker Scholar. He also received his AB from Harvard College.
Scott Kirsner is a journalist who writes about innovation and entrepreneurship. His “Innovation Economy” column appears Sundays in the Boston Globe, and he also writes a companion blog at boston.com/innovation. Scott has been a regular contributor to Fast Company, BusinessWeek,Variety, and Wired. Scott’s writing has also appeared in the New York Times, The Hollywood Reporter, Salon, the San Jose Mercury News, and Newsweek, among other publications.Scott Kirsner:
John Lauerman is an award-winning reporter covering health and higher education for Bloomberg News in Boston. Recently he has chronicled his experiences as a participant in the Personal Genome Project. In 2011, he and his colleagues won a Polk Award and were Pulitzer finalists for a series of stories on for-profit colleges that recruit low-income students, often to leave them with debt and no degree. He's been a fellow of the Blue Cross Blue Shield of Massachusetts Health Coverage program; the Kaiser Family Foundation's program for science journalists and Harvard Medical School's Media Fellowship. He lives with his wife and two children in Brookline, Massachusetts.
Crystal Mackall, MD is Head of Immunology Section and Chief of the Pediatric Oncology Branch at the National Cancer Institute, leading a translational research program focused on developing new immune based therapies for childhood cancer. She is an expert in the field of T cell homeostasis and led clinical development of recombinant interleukin-7, conducting first-in-human studies with this agent. She has developed dendritic cell based vaccines for pediatric sarcomas, is leading clinical trials of adoptive T cell and NK cell therapies, and is a leader in the emerging field of using engineered T cells to treat hematologic and solid tumors. Dr. Mackall co-Leads the StandUp2Cancer/St.Baldrick’s/NCI Pediatric Dream Team, which focuses on development of immune based therapies for childhood cancer.
Dr. Mandl is a Professor at Harvard Medical School and Director of the Boston Children’s Computational Health Informatics Program. Through scholarship intersecting epidemiology and informatics, Mandl pioneered use of IT and big data for population health, discovery, patient engagement and care redesign. Mandl leads the transformative SMART Platforms initiative to design the app store for health and is principal investigator of the Scalable Collaborative Infrastructure for a Learning Health System across Boston hospitals and nationally. His clinical training and experience is in pediatrics and pediatric emergency medicine. Dr. Mandl has been elected to multiple honor societies including the American College of Medical Informatics, American Society for Clinical Investigation, Society for Pediatric Research, and American Pediatric Society.Kenneth Mandl, MD, MPH:
David Meeker was appointed CEO of Genzyme in October 2011. In his career with Genzyme, he has held key positions of increasing responsibility, most recently as Chief Operating Officer. In this role, he was responsible for Genzyme’s commercial organization, overseeing its business units, country management organization, and global market access functions. As Chief Operating Officer, he played an important role in the integration with Sanofi.
Melinda Merchant, MD, PhD, is the Senior Medical Director in Oncology, Early Clinical Development at AstraZeneca R&D. Dr. Merchant’s clinical and translational career has been focused on sarcoma and other rare solid tumors in pediatric and young adult patients. As a pediatric oncologist and clinician-scientist at the National Cancer Institute and Memorial Sloan-Kettering Cancer Center, she lead clinical trials in immunotherapy and personalized medicine and recently completed 5 years of service on the NCI IRB. Dr. Merchant is currently focused on small molecules for ImmunoOncology with a goal to promote efficient development of new therapeutics to the clinic, including an earlier introduction to pediatrics and other rare tumors. She works closely with translational scientists at AstraZeneca to deliver programs that move forward the clinical application of new drugs and enable feed back into basic science questions relating to genomics, biomarkers, and immune escape mechanisms.
Dr. Might's passion has been accelerating the promise of precision medicine for patients since 2012, when his son was diagnosed via sequencing as the first known case of NGLY1 deficiency. Dr. Might is currently a Visiting Associate Professor in Biomedical Informatics at the Harvard Medical School. He has been actively engaged with White House and NIH leadership on the Precision Medicine Initiative, serving as an ardent advocate for translational science in the initiative. Dr. Might is also an Associate Professor in Computer Science at the University of Utah. His work is actively funded by DARPA, NSF and the National Nuclear Security Administration. In 2014, he was appointed one of six Presidential Scholars at the University of Utah. He received his Ph.D. in Computer Science from Georgia Tech in 2007.Matthew Might:
Kara Miller is the host and executive editor of “Innovation Hub,” from WGBH and PRI, which she started in 2011. The show focuses on creative thinking in areas from healthcare to transportation, technology to education. Kara also contributes to “The Takeaway,” a national radio program hosted by John Hockenberry, and WGBH’s “Morning Edition.” She has served as a TV analyst for both WGBH and NECN. Kara’s writing has appeared in The Boston Globe, The National Journal, The Boston Herald, TheAtlantic.com, The Huffington Post, and The International Herald Tribune. She holds a Ph.D. from Tufts and a B.A. from Yale. She has taught at the University of Massachusetts and Babson College.Kara Miller:
Dr. Siddhartha Mukherjee is a renowned oncologist, cancer researcher and Pulitzer Prize-winning author of "The Emperor of All Maladies: A Biography of Cancer". Dr. Mukherjee earned his B.S. at Stanford University, his doctorate at Harvard Medical School, and his PhD in immunology at Oxford. His credentials include assistant professor of medicine at Columbia University, physician at Columbia/NYU Presbyterian, and fellow at Dana Farber Cancer Institute. His book has won numerous awards and was featured in the 2015 Ken Burns PBS documentary by the same name.
Martha Murray, MD, is an orthopaedic surgeon at Boston Children's Hospital. She has developed a novel technique of ACL repair which utilizes a bridge-enhanced scaffold to stimulate healing of the ligament instead of the traditional harvesting of a graft of tendon to replace the torn ACL. She was named one of Fast Company's Top 100 Most Creative People in Business in 2015, as well as being featured in Stephen Hawking's Brave New World Series for this bench-to-bedside work. Martha has a BS in Mechanical Engineering from the University of Delaware, a MS in Engineering from Stanford, andreceived her MD from the University of Pennsylvania prior to completing residencies and fellowships at Harvard Medical School.
Jason Robart is the President and CEO of Zaffre Investments, a wholly owned subsidiary of Blue Cross Blue Shield of Massachusetts. Zaffre is committed to adding value through investments in new products, services, and technology, to improve the way healthcare is delivered and received. Jason also serves as the Interim Chief Strategy Officer for Blue Cross.Previously Jason served as Blue Cross’ Senior Vice President of Organizational Effectiveness and Chief Human Resources Officer. He has more than 20 years of experience in health care, human resources, client relationship development, and sales/product management.
Martine Rothblatt is Chairman & Co-CEO of United Therapeutics Corporation, and President & CEO of its Lung Biotechnology public benefit company. She previously created and led Sirius XM as its Chairman & CEO. She has JD and MBA degrees from UCLA, and a Ph.D. in Medical Ethics from the Royal London School of Medicine & Dentistry. Her patented inventions cover aspects of satellite radio, prostacyclin biochemistry and cognitive software. Dr. Rothblatt’s most recent books are on xenotransplantation (Your Life or Mine, Ashgate) and cyberethics (Virtually Human, St. Martin’s).
Jeff Ruiz is the Vice President, Diabetes Service and Solutions, Americas Region at Medtronic. He has previously held key positions with leading medical technology companies including United States Surgical Corporation, C.R. Bard, and his own entrepreneurial endeavors. For over 15 years, Jeff has succeeded in various leadership roles throughout Medtronic including areas of Sales, Marketing, Business Operations, and Customer Service. Ruiz was instrumental in building the sustainable Diabetes Therapy Management Center in San Antonio, Texas. Recently Medtronic awarded Jeff with the Wallin Leadership Award winner (2014). In 2008, Jeff was the recipient of Medtronic’s prestigious Global Leadership Award.
Dr. Salgo currently serves as Associate Chief Medical Officer for Patient Care and Monitoring Systems at Philips Healthcare. He explores business development opportunities for new technologies and clinical needs. He has ten years of experience in academic medicine at the University of Pennsylvania in Cardiothoracic Anesthesiology and Intraoperative Echocardiography and has conducted NIH-funded research in cardiac mechanics and imaging. Dr. Salgo also has extensive corporate experience in R&D product development, market positioning and strategy, and evidence-based medicine validation, and has successfully led medical device development teams.
Gregory S. Sawicki, MD, MPH, is a pediatric pulmonologist and health services researcher with particular interest in addressing health outcomes, disease self-management, and adherence for children, adolescents, and young adults with chronic respiratory diseases including cystic fibrosis (CF) and asthma. Dr. Sawicki’s primary research activities are currently focused on the process and outcomes of transition from pediatric to adult focused health care for adolescents with chronic medical conditions. He is conducting a NIH-funded mixed methods qualitative and survey study of adolescents and young adults with CF with the aim of exploring their current experiences with health care transition and disease self-management. In his recent work, he has helped to develop and validate a survey instrument to assess transition readiness for youth with chronic disease, the Transition Readiness Assessment Questionnaire (TRAQ). This instrument is currently being used in multiple health care transition studies throughout the country. He also is working on the development of quality measures to evaluate the transition to adult care for youth with chronic conditions.
Gregory Steinberg serves as the Head of Clinical Innovation at Aetna. He was previously the CEO and President of ActiveHealth Management between 2010 and 2011, and their Chief Medical Officer between 2000 and 2010. Prior to ActiveHealth, Greg was the Associate Director of Medicine at St. Luke’s-Roosevelt Hospital Center in New York City from 1992-2000, and an Associate Clinical Professor of Medicine at the Columbia University College of Physicians and Surgeons. He currently is an Emeritus Attending Physician at St. Luke's-Roosevelt Hospital Center. Greg received his medical degree from the Welsh National School of Medicine in 1978, trained in Internal Medicine and Cardiovascular Disease at St. Luke’s Roosevelt in New York City, and is board-certified in Internal Medicine (1985) and Cardiovascular Diseases (1987).
Dr. Stevens is a Research Associate in Neurology at Boston Children’s Hospital and a recently announced 2015 MacArthur Fellow for her work establishing the unexpected role of immune cells in sculpting the brain's circuitry. She received her PhD in Neuroscience in 2003 from the University of Maryland, College Park and completed her postdoctoral fellowship at the Stanford University School of Medicine in 2008. She is a recipient of the 2008 Smith Family Award for Excellence in Biomedical Research, a 2010 Dana Foundation Award (Brain and Immunoimaging) and a 2010 Ellison Medical Foundation New Scholar in Aging award. In 2012, she received a Presidential Early Career Award for Scientists and Engineers.
Luke Timmerman is a biotechnology journalist, author, and entrepreneur. He is the founder and editor of Timmerman Report, a subscription publication for biotech insiders, and is a contributing writer at Forbes. He is currently working on his first book, a biography of biotech pioneer Lee Hood. Previously, Luke covered biotech at The Seattle Times, Xconomy, and Bloomberg News. Luke has a bachelor’s in journalism from the University of Wisconsin, and was awarded a Knight Science Journalism Fellowship at MIT.Luke Timmerman:
Dr. Timothy Triche is the founding Director for the Children’s Hospital Los Angeles Center for Personalized Medicine. He previously served as Chief of the Department of Pathology and Laboratory Medicine for over 20 years. He is also Professor of Pathology and Pediatrics at the Keck School of Medicine of the University of Southern California. At Children’s Hospital, his research is focused on high-risk childhood cancer, including molecular diagnostics and nanoparticle therapeutics, as part of an overall focus on ‘precision’ or ‘personalized’ treatment of childhood cancer.
Dominique Verhelle is a strategic advisor at Third Rock Ventures. She previously worked as a Director at Pfizer in the Tumor Cell Biology Group, Oncology Research Unit where she lead the effort in Epigenetic research applied to cancer therapies and manages a team of scientists involved in drug discovery programs. Dominique has 21 years of experience in research focusing mainly on oncology and started her career in industry at Celgene. Dominique holds a PhD in Life Sciences from the University of Nice Sophia Antipolis, France and earned an MBA from The Rady School of Management, San Diego in 2009.
Andrew M. Wiesenthal, MD, SM is a Director in Health Care Practice at Deloitte. Previously, he was Associate Executive Director of the Permanente Federation where he worked in the arenas of development and deployment of automated medical records, decision support, and other clinical systems. Dr. Wiesenthal served as a pediatrician and pediatric infectious diseases consultant with the Colorado Permanente Medical Group (CPMG). Since joining Deloitte, he has been a leader on clinical information system projects and health care delivery system strategy. Dr. Wiesenthal received his BA from Yale, MD from the State University of New York Downstate Medical Center in Brooklyn, completed his pediatric residency and pediatric infectious disease fellowship at the University of Colorado, and earned an SM in Health Care Management from the Harvard School of Public Health.
Jackson is a product design & engineering leader and the Founder of Kinsights, a unique community that helps parents make better, more confident decisions. Previously, Jackson was Director of User Experience at Posterous (acquired by Twitter), design lead at LinkedIn, and founded the user experience team at Viget, a top agency in Washington. He has worked with dozens of startups, mature companies, and the White House to build engaging products that help solve real problems for real people. Jackson has an AB cum laude in music and philosophy from Bowdoin College.M. Jackson Wilkinson:
Dr. Williams is the Chief of Hematology/Oncology and Director of Clinical and Translational Research at Boston Children’s Hospital and Associate Chairman, Department of Pediatric Oncology at Dana-Farber Cancer Institute. He is Director of the Pediatric Hematology/Oncology Fellowship Training Program at BCH/DFCI. He was a Howard Hughes Medical Institute Investigator for 16 years and his laboratory has been continuously NIH funded since 1986. He is actively involved in gene therapy trials for blood, immunodeficiency and neurological genetic diseases and has been the investigator, co-investigator or sponsor (IND holder) of four previous gene therapy trials and is sponsor, investigator or co-investigator of four current trials.
Dr. Bruce Zetter, PhD is a Charles Nowiszewski Professor of Cancer Biology in the Vascular Biology Program at Boston Children’s Hospital and Harvard Medical School. He is highly regarded nationally and internationally as a leader in the research of tumor progression, cancer diagnosis, cancer metastasis, and tumor angiogenesis. His current research interests are focused on tumor metastasis, novel cancer treatments and on tests that predict future outcomes for cancer patients. From ‘04-’08, Zetter served as Chief Scientific Officer of Boston Children’s. Dr. Zetter has won numerous national and international awards including a Faculty Research Award from the American Cancer Society and the prestigious MERIT award from the US National Cancer Institute.
Daphne Zohar is co-founder and CEO of PureTech, a science-driven healthcare company seeking to solve some of today’s toughest health challenges through disruptive approaches. Ms. Zohar has been recognized as a top leader and innovator in biotechnology by BioWorld, MIT's Technology Review, the Boston Globe, and Scientific American. She sits on the boards of PureTech LLC, the Sync Project, Follica, Akili, Karuna and Tal. She also sits on the Technology Development Fund Advisory Board at Children's Hospital Boston and is an Editorial Advisor to Xconomy.Daphne Zohar: